Trulieve has seen a dramatic decline, dropping 18.2% in 2025 and 92.1% since its 2021 peak. Financial pressures persist with declining operating income, despite slight revenue growth and high adjusted ...

Trulieve's stock price is near a one-year high, outperforming other MSOs but not Tier 1 MSOs. Trulieve's growth is expected to be sluggish due to its dependence on the mature medical-only Florida ...

Trulieve's acquisition of Harvest Health puts it in a neck-and-neck race with Curaleaf. Below, I'll look at which business will likely bring in more revenue in 2022. That could be key in determining ...

Less than a month after short seller Grizzly Research published a report claiming that Trulieve Cannabis Corp (OTC: TCNNF) is “a fraud,” Trulieve has filed a lawsuit against Grizzly Research, ...

This should be the best of times for Trulieve. The medical marijuana company sold more than half of all the smokable cannabis distributed to patients in Florida last month. It’s recorded 14 straight ...